

Research

Open Access

Reanalysis of cancer mortality in Japanese A-bomb survivors exposed to low doses of radiation: bootstrap and simulation methods

Greg Dropkin

Address: Flat 5, 32 Sheil Road, Liverpool L6 3AE, UK

E-mail: gregd@gn.apc.org

Published: 9 December 2009

Received: 3 February 2009

Environmental Health 2009, **8**:56 doi: 10.1186/1476-069X-8-56

Accepted: 9 December 2009

This article is available from: <http://www.ehjournal.net/content/8/1/56>

© 2009 Dropkin; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The International Commission on Radiological Protection (ICRP) recommended annual occupational dose limit is 20 mSv. Cancer mortality in Japanese A-bomb survivors exposed to less than 20 mSv external radiation in 1945 was analysed previously, using a latency model with non-linear dose response. Questions were raised regarding statistical inference with this model.

Methods: Cancers with over 100 deaths in the 0 - 20 mSv subcohort of the 1950-1990 Life Span Study are analysed with Poisson regression models incorporating latency, allowing linear and non-linear dose response. Bootstrap percentile and Bias-corrected accelerated (BCa) methods and simulation of the Likelihood Ratio Test lead to Confidence Intervals for Excess Relative Risk (ERR) and tests against the linear model.

Results: The linear model shows significant large, positive values of ERR for liver and urinary cancers at latencies from 37 - 43 years. Dose response below 20 mSv is strongly non-linear at the optimal latencies for the stomach (11.89 years), liver (36.9), lung (13.6), leukaemia (23.66), and pancreas (11.86) and across broad latency ranges. Confidence Intervals for ERR are comparable using Bootstrap and Likelihood Ratio Test methods and BCa 95% Confidence Intervals are strictly positive across latency ranges for all 5 cancers. Similar risk estimates for 10 mSv (lagged dose) are obtained from the 0 - 20 mSv and 5 - 500 mSv data for the stomach, liver, lung and leukaemia. Dose response for the latter 3 cancers is significantly non-linear in the 5 - 500 mSv range.

Conclusion: Liver and urinary cancer mortality risk is significantly raised using a latency model with linear dose response. A non-linear model is strongly superior for the stomach, liver, lung, pancreas and leukaemia. Bootstrap and Likelihood-based confidence intervals are broadly comparable and ERR is strictly positive by bootstrap methods for all 5 cancers. Except for the pancreas, similar estimates of latency and risk from 10 mSv are obtained from the 0 - 20 mSv and 5 - 500 mSv subcohorts. Large and significant cancer risks for Japanese survivors exposed to less than 20 mSv external radiation from the atomic bombs in 1945 cast doubt on the ICRP recommended annual occupational dose limit.

Background

Analyses of cancer mortality in survivors of the atomic bombing of Japan in 1945 have played a central role in establishing risk estimates and radiation protection limits for workers and the wider public. While many people exposed at Hiroshima and Nagasaki received fairly high doses, the recommended occupational and environmental dose limits aim to control the risks from much lower doses. Typically, analyses of the full cohort of Japanese survivors, whose doses ranged from 0 - 4000 mSv or more, are extrapolated downwards to predict the risks from doses below 20 mSv [1]. However, even if a particular model gives a good overall account of the full range of data, fitting that model and extrapolating the results may misrepresent the risks at low doses where the dose response may be quite distinct.

My previous paper [2] considered the cancer mortality data for those survivors whose external (flash) dose from the A-bombs was below 20 mSv, the annual occupational dose limit recommended by the International Commission on Radiological Protection (ICRP). I applied several different models, each of which used as their exposure variable the radiation dose lagged by an unknown latency. One model adopted the standard assumption that Excess Relative Risk (ERR) is proportional to dose, in this case the lagged dose. Other models allowed that ERR might be a non-linear function of dose, as suggested by radiation cell biology studies of the bystander effect. All the models detected ERR values for a dose of 10 mSv which were far higher than predicted by extrapolating the standard analyses of the full cohort. The linear model found large, significant results for the liver, while the preferred non-linear model found large, significant results for the stomach, liver, and lung. These results occurred over a range of latencies.

The statistical method I used to assess the significance of the findings with non-linear models was criticised by Mark Little [3]. In this paper the data is re-analysed with other methods of statistical inference for the preferred non-linear model.

The models use Poisson regression to analyse the grouped data in the 0 - 20 mSv subcohort of the 1950-1990 Life Span Study LSS12 [4]. The models take the form $\lambda = \lambda_0(1+ERR)$ where λ is the cancer risk, λ_0 depends only on control variables, and ERR depends only on the lagged radiation dose. Profile Likelihood Confidence Intervals for ERR were based in [2] on the Likelihood Ratio Test (LRT) for comparisons between nested models. Once latency is fixed, the models depend smoothly on all other parameters. If Wilks Theorem [5] holds, the asymptotic null distribution of LRT is χ^2 on d degrees of freedom when the null hypothesis is specified by fixing

the values of d parameters in the wider model. For example, the LRT comparison of the linear model $ERR = \beta D$ with the control model $ERR = 0$ is asymptotically χ^2 on 1 d.f. if the control model holds. Here the null hypothesis is $\beta = 0$ and Wilks Theorem does apply to this nested pair. As Little [3] pointed out, the non-linear models are less well behaved. The transient model $ERR = \sigma \text{Dexp}(-\tau D)$ and the two-phase model $ERR = \beta D + \sigma \text{Dexp}(-\tau D)$ are indeterminate in τ when $\sigma = 0$, so one of the regularity conditions for Wilks Theorem fails. In any case, even if the asymptotic null distribution of LRT were known, the distribution for a given finite set of records may differ from the asymptotic case.

However, the actual distribution of LRT can be estimated by simulation before comparing two competing models or constructing confidence intervals. Bootstrap methods [6,7] can also be used to construct confidence intervals more directly.

In response to questions raised during peer review I also consider whether the data justifies fitting the two-phase model, investigate uncertainties in the "optimal latency" as estimated from the data, extend the analysis to include the covariate "city", and compare results from the 0 - 20 mSv and 5 - 500 mSv dose ranges.

Methods

An initial analysis of latency is carried out for all cancer sites with at least 100 cases (deaths) in the 0 - 20 mSv subcohort. Sites which appear to have a raised dose response are then analysed by the bootstrap and the distribution of LRT is estimated by simulation. A fuller simulation is carried out for the stomach, the site with the largest number of cases in this subcohort. The analysis focuses on the behaviour of the two-phase model (defined below) and its relation to the linear model. It aims to compare confidence intervals obtained by bootstrap and LRT simulation methods and to discover without relying on Wilks Theorem, whether the apparent elevation and non-linearity of the dose response in the 0 - 20 mSv subcohort are statistically significant. Further analysis considers variation in latency, the impact of "city", male and female subcohorts, and the 5 - 500 mSv dose range. Computations use the statistical freeware **R** [8], giving a further check on previous results. Possible sources of error in the Japanese data itself and the potential for confounding by other covariates as discussed in [2], are not reconsidered here.

As previously source data for the 1950-1990 mortality cohort LSS12 was obtained from RERF [9] via the CEDR [10], and the 0 - 20 mSv subcohort defined by restricting the weighted adjusted colon dose. The subcohort comprises

3011 data cells with 1690391.75 p-y. The control model, linear model, and two-phase model are defined as in [2]. Briefly, the control model is log-linear in 14 indicator variables for 5 year age-at-exposure categories, an indicator for gender, and the numerical variable log mean attained age, each of which is well-defined for the data cells. The control model is specified as $\lambda = \lambda_0 = \exp(\alpha + \sum \beta_j x_j)$ where α and the β_j are unknown parameters, x_j are the covariates, \exp denotes exponential, and the Poisson parameter in cell i with T_i person-years is $\lambda_i T_i$ where λ_i is evaluated using the covariates in cell i . At this stage, as in [2], "city" (Hiroshima or Nagasaki) is not included as a covariate.

Other models are defined by $\lambda = \lambda_0(1+ERR)$ where ERR depends only on D_ϕ , the radiation dose lagged by a latency parameter ϕ . D_ϕ is defined as the weighted adjusted colon dose in 10 mSv units when time-since-exposure $\geq \phi$, and 0 otherwise.

For the linear model, $ERR = \beta D_\phi$

For the two-phase model, $ERR = \beta D_\phi + \sigma D_\phi \exp(-\tau D_\phi)$ where \exp denotes exponential.

The models require $1+ERR > 0$ in all cells so that the Poisson distributions are defined. For the two-phase model $\tau > 0$, slightly modifying the previous approach where $\tau \geq 0$. However, $\tau = 0$ reduces to the linear model as does $\sigma = 0$.

In fitting a model at latency ϕ by Poisson regression, the unknown parameters α, β_j and β, σ, τ (as appropriate to the model) are chosen to maximise the likelihood of the observed data assuming independent Poisson distributions in each cell. Equivalently, fitting minimises the sum over the 3011 data cells of $E_i - O_i \ln(E_i)$, where O_i and $E_i = \lambda_i T_i$ are the observed and expected number of cases in cell i .

Latency ϕ is fixed during the minimisation. The models depend smoothly on all other parameters. $ERR_{D,\phi}$ denotes the Excess Relative Risk evaluated at D for the fitted model with latency ϕ . Note $ERR_{1,\phi}$ is the estimated risk at 10 mSv lagged by ϕ years. For model I nested within model J , $LRT_{I-1,\phi}$ is the Likelihood Ratio Test computed at latency ϕ .

Code written in **R** emulates the previous model fitting with Excel-Solver, using the Newton-Raphson minimisation routine "optim" [11]. Results for the stomach at latency $\phi = 5, 6, \dots, 44$ are checked against the values obtained previously.

At a given cancer site, the control, linear, and two-phase models are fitted at latency $\phi = 5, 6, \dots, 44$ to give $LRT_{I-1,\phi}$ for each pair of nested models: linear against control, two-

phase against control, and two-phase against linear. Sites are selected for further analysis if $LRT_{lin-con,\phi} > 4$ for some ϕ , or if $LRT_{2p-lin,\phi} > 6$ for some ϕ (not assuming that this criterion establishes statistical significance). For sites meeting the criterion for the linear model, Profile Likelihood Confidence Intervals for $\beta = ERR_{1,\phi}$ are computed using Wilks Theorem at integer values of ϕ . For sites meeting the criterion for the two-phase model, $\phi = \phi_{mabs}$ is chosen to maximise $LRT_{2p-con,\phi}$ (not $LRT_{2p-lin,\phi}$) so that fitting at ϕ_{mabs} gives the absolute Maximum Likelihood Estimate (MLE) for the model. The "optimal latency" ϕ_m is chosen to maximise $LRT_{2p-con,\phi}$ subject to the constraint $ERR_{1,\phi} \geq 0$. Bootstrap confidence intervals and LRT simulations are then computed at ϕ_m . Details are given in the next two more technical subsections, and examples with commentary are supplied with Additional File 1. The method for taking account of uncertainty in the "optimal latency" is outlined in a final subsection.

Bootstrap

Fitting the two-phase model at $\phi = \phi_m$ gives a maximum likelihood estimate $\hat{\psi}$ for the vector of all 20 model parameters and determines fitted values of λ_i in each data cell. The parametric bootstrap assumes the observed data arose from sampling this fitted model, and considers the variation arising if other data had been sampled from that same model.

Sampling the independent Poisson distributions with parameters $\lambda_i T_i$ gives simulated observations in each data cell. Fitting the two-phase model to this simulated data gives simulated parameter values including $\hat{\beta}, \hat{\sigma}$ and $\hat{\tau}$, and therefore a simulated value of $ERR = ERR_{D,\phi} = \hat{\beta} D_\phi + \hat{\sigma} D_\phi \exp(-\hat{\tau} D_\phi)$. The entire process is repeated B times to give the bootstrap replications ERR^* .

There are many well-established methods to obtain confidence intervals from bootstrap replications [7,12]. The two options chosen here are the original "percentile" method, which is easy to describe, and the "Bias-corrected accelerated" method which is much faster to compute, and in general more accurate.

The $1-2\alpha$ "percentile" confidence interval has endpoints

$$ERR^*_{(B\alpha)}, ERR^*_{(B(1-\alpha))}$$

where $ERR^*_{(B\alpha)}$ denotes the $B\alpha^{th}$ ordered value of ERR^* . With $B = 1000$ replications and $\alpha = 0.025$, the endpoints of the 0.95 percentile interval are the 25th and 975th order statistics of ERR^* .

For the Bias-corrected accelerated (BC_a) confidence interval (see [7] Chapter 5 pp. 203-207 and p.249)

simulation is again carried out using $\lambda_i T_i$. However, the simulated observations are now used to fit the model to the "Least Favourable family" of distributions, obtained by restricting the parameter vector ψ to a line parametrised by ζ , passing through the MLE $\hat{\psi}$ and defined by $\psi = \hat{\psi} + \zeta \hat{\delta}$ where

$$\hat{\delta} = i^{-1}(\hat{\psi}) \dot{h}(\psi)$$

Here $i^{-1}(\hat{\psi})$ is the inverse of the Fisher Information evaluated at $\hat{\psi}$ and $\dot{h}(\psi)$ is the gradient of the function h which defines the variable of interest (in this case ERR) in terms of the model parameters ψ .

For each bootstrap replication, fitting the simulated data along the LF family determines ζ and thus the simulated value $ERR = h(\psi + \zeta \delta)$. If ERR^*_{LF} denotes the resulting set of B replications, the BC_a confidence interval has endpoints

$$ERR^*_{LF(B\alpha_1)}, ERR^*_{LF(B\alpha_2)}$$

where

$$\alpha_1 = \Phi(w + (w + z^{(\alpha)}) / (1 - a(w + z^{(\alpha)})))$$

$$\alpha_2 = \Phi(w + (w + z^{(1-\alpha)}) / (1 - a(w + z^{(1-\alpha)})))$$

Here Φ is the standard normal cumulative distribution and $z^{(\alpha)}$ is the 100α th percentile point of a standard normal distribution. The parameters w and a are estimated from the bootstrap replicates. The bias-correction w is computed as

$$w = \Phi^{-1}(\{ \# \{ ERR^*_{LF} < ERR \} \} / B)$$

i.e. the fraction of bootstrap replications along the LF family which are below the original fitted value of ERR, in normal units.

The acceleration a is computed as

$$a = 1/6 m_3 / (m_2)^{3/2}$$

where m_3 and m_2 are the 3rd and 2nd moments of $\dot{\ell}^*_{LF}(0)$, the partial derivative of the log likelihood of the simulated data with respect to ζ , evaluated at $\zeta = 0$.

Code for this calculation is shown in Additional File 1, Code File AC1.txt, which calls Additional File 1, Data Files stomdat1.txt, lambda2.txt and theta2.txt. Additional File 1, Commentary File ACom1.doc discusses this code.

Despite the intricate formulas, computation is much faster for BC_a than for the simpler percentile method,

because optimisation is now restricted to a line within the full 20-dimensional parameter space. The percentile CIs are computed at $B = 1000$, the recommended minimum number, while BC_a results are obtained at $B = 5000$.

Coverage for the percentile and BC_a methods is tested using the stomach data. For each of 400 sets of simulated observations generated by sampling the Poisson distributions determined by the original fitted parameters, the model is refitted to the simulated data. Confidence intervals for the simulated ERR are obtained by the bootstrap methods ($B = 1000$) using the refitted parameters and counted as 1 or 0 if they contain or exclude the "true" value of ERR from the original fitted parameters. To streamline these computations of coverage for the percentile method, data is restricted to the Hiroshima subcohort ($N = 1536$ cells) and the model simplified to use 10-year rather than 5-year age-at-exposure categories. Estimating coverage for the BC_a method uses the full 0 - 20 mSv dataset and model. The application of both methods to compute CIs from the observed data uses the full dataset and model.

Simulation of LRT

The Likelihood Ratio Test (LRT) for comparing nested models $H_0 \leq H_1$ (H_0 contained within H_1) given the observed data \mathcal{D} is $LRT = 2[\mathcal{L}(H_1, \mathcal{D}) - \mathcal{L}(H_0, \mathcal{D})]$ where $\mathcal{L}(H_i, \mathcal{D})$ is the log likelihood of the observed data after fitting the model H_i . In well-behaved situations where Wilks theorem [5] applies, the asymptotic distribution of LRT is known, provided the data was drawn from a distribution which satisfies the null hypothesis H_0 . In particular, an appropriate critical value $t_{0.95}$ can be chosen for rejecting H_0 if $LRT > t_{0.95}$ and this will result in a 5% error rate of rejecting H_0 when it is true. Typically H_0 fixes the values of d parameters in the full model H_1 which allows those parameters to vary freely in an open neighbourhood. In this case Wilks theorem says that LRT is asymptotically χ^2 distributed on d degrees of freedom if the observed data was generated by the model with those d parameters fixed as specified. On that basis, the null hypothesis can be rejected if $LRT > t_{0.95} = F^{-1}(0.95)$ where F is the cumulative of a χ^2 distribution on d degrees of freedom.

Wilks theorem depends on many regularity conditions for the models H_0 and H_1 . If these fail, LRT may not be χ^2 distributed; its distribution may depend on H_0 rather than just on the number of specified parameters, and there may be no simple universal 95% critical value for rejecting H_0 . Simulation aims to estimate the distribution of LRT and then to obtain conservative critical values which are sufficient to reject H_0 . Confidence

intervals for functions of the parameters are constructed using these critical values.

For the two-phase model LRT_{2p-H_0} is the Likelihood Ratio Test for the hypothesis $H_0: (\beta, \sigma, \tau) = (\beta_0, \sigma_0, \tau_0)$ vs. the alternative $(\beta, \sigma, \tau) \neq (\beta_0, \sigma_0, \tau_0)$, i.e. H_1 is the union of H_0 with its alternative, and leaves (β, σ, τ) free to vary, subject only to the defining conditions of the two-phase model. For various choices of H_0 the null distribution of LRT_{2p-H_0} assuming H_0 holds is sampled by Monte Carlo simulation (see [7] Chapter 4; for another context see [13] p.84) as follows.

One) The model is fitted subject to H_0 . The resulting parameter estimates give fitted values $\hat{\lambda}_{0i}$ and therefore $\hat{\lambda}_{0i} T_i$ for each cell, subject to H_0 .

Two) Poisson distributions with parameters $\hat{\lambda}_{0i} T_i$ are sampled independently to give simulated cases \tilde{O}_i in each cell.

Three) The model is fitted to the simulated data \tilde{O}_i subject to H_0 , yielding new fitted values $\tilde{\lambda}_{0i}$ for each cell. Put $K_0 = -2 \sum_1^{3011} (\tilde{O}_i \ln \tilde{\lambda}_{0i} - \tilde{\lambda}_{0i})$.

Four) The model is fitted to the simulated data \tilde{O}_i with (β, σ, τ) allowed to vary freely within the parameter space, yielding new fitted values $\tilde{\lambda}_i$ for each cell. Put $K = -2 \sum_1^{3011} (\tilde{O}_i \ln \tilde{\lambda}_i - \tilde{\lambda}_i)$. The simulated value of LRT_{2p-H_0} is defined as $LRT^* = K_0 - K$. Note that up to a constant which depends on the simulated data \tilde{O} but not on the model, $K_0 = -2\mathcal{L}(H_0, \tilde{O})$ while $K = -2\mathcal{L}(H_1, \tilde{O})$.

Five) Steps Two through Four are repeated 500 (or 1000) times to give the sample LRT^* .

An example of the required code is given in Additional File 1, Code File AC2.txt which calls Additional File 1, Data Files stomdat1.txt, lambda1.txt, theta1.txt, and Additional File 1, Code File AC2s.txt. Additional File 1, Commentary File ACom2.doc discusses this code.

While step Four is time-consuming, steps One and Three are quick as the model is log-linear in the remaining parameters. Step Two is trivial in R. Note that in step Four the possible values of (β, σ, τ) are still constrained by the requirement that $1+ERR > 0$ in all cells. For computability, the constraint is set at $1+ERR \geq 0.001$.

To check whether Wilks theorem holds, LRT^* is first tested against a χ^2 distribution on 3 d.f. by the Kolmogorov-Smirnov (one-sample) test. LRT^* is then tested against gamma distributions with unknown shape and rate parameters. A γ distribution is fitted to LRT^*

using the "fitdistr" subroutine of R (MASS library) [14]. When testing LRT^* against the fitted distribution with shape parameter \hat{s} and rate parameter \hat{r} , the Kolmogorov statistic D is obtained from the (one sample) K-S test but its p-value is determined by simulation (as in the Lilliefors test). When LRT^* has 500 elements, 500 random deviates are taken from the fitted γ distribution with parameters \hat{s} and \hat{r} to form a sample S , a new gamma distribution Γ is fitted to S , the K-S statistic D^* for testing S against Γ (one-sample) is computed, and the process is repeated 5000x to estimate the probability that $D^* > D$ when samples are drawn from $\gamma(\hat{s}, \hat{r})$. R code was adapted from [15].

For the special case $(\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$ the sample LRT^* uses 1000 replications; note that in this case $LRT_{2p-H_0} = LRT_{2p-con}$. Likewise at the MLE estimate $(\hat{\beta}, \hat{\sigma}, \hat{\tau})$, LRT^* is produced during the (percentile) bootstrap with 1000 replications. In both cases the simulations required for the p-value of D use 1000 random deviates of the fitted γ distribution.

For the liver, lung, pancreas and leukaemia, LRT simulation ($\times 1000$) is carried out at $(0, 0, \text{arbitrary})$ and $(\hat{\beta}, \hat{\sigma}, \hat{\tau})$, and ($\times 500$) at 3 points chosen at random with $\sigma_0 = 0$ and β_0 in the intervals $-0.5 < \beta_0 < 0$, $0 < \beta_0 < 1$, and $1 < \beta_0 < 10$, and also at 4 points chosen at random in a neighbourhood N_{10} of $(\hat{\beta}, \hat{\sigma}, \hat{\tau})$. N_{10} comprises those $(\beta_0, \sigma_0, \tau_0)$ for which the observed (not simulated) $LRT_{2p-H_0} < 10$. Each set of simulations gives a sample LRT_i^* and corresponding fitted gamma distributions γ_i .

For the stomach, simulations and corresponding fitted γ_i are carried out at the MLE and 50 other random points in the parameter space: ($\times 500$) at 11 points with $\sigma_0 = 0$, 4 points in a neighbourhood N_{10} of $(\hat{\beta}, \hat{\sigma}, \hat{\tau})$, 34 other points in the (β, σ, τ) parameter space, and ($\times 1000$) at $(0, 0, \text{arbitrary})$ and $(\hat{\beta}, \hat{\sigma}, \hat{\tau})$.

Estimates of a 95% critical value for the null distribution of LRT are then obtained in three ways. For each cancer site, the fitted gamma distributions and the order statistics of the simulated LRT_i^* are used to estimate a global 95% critical value as $t'_{.95} = \max(\sup(t_{.95,i}), \sup(s_{.95,i}))$ where $t_{.95,i}$ is the 95th percentile of γ_i and $s_{.95,i}$ is the 95th percentile of LRT_i^* . That is, at each value of $(\beta_0, \sigma_0, \tau_0)$ tested for a particular site, 95% of the simulated LRT values and the 95th percentile of the fitted gamma distribution are both below $t'_{.95}$. An overall conservative estimate $t_{.95}$ is chosen to exceed the corresponding maximum for all simulations and all cancer sites investigated. At each site, a refined estimate $t''_{.95} = \max(\sup(t_{.95,i}))$ is obtained by considering only the fitted gamma distributions and restricting to simulations at points $(\beta_0, \sigma_0, \tau_0)$ within N_{10} . At each cancer site $t''_{.95} \leq t'_{.95} \leq t_{.95}$.

The neighbourhood N_{10} of $(\hat{\beta}, \hat{\sigma}, \hat{\tau})$ is termed “appropriate” if the overall estimate $t_{.95} \leq 10$ so that for $(\beta_0, \sigma_0, \tau_0)$ outside N_{10} , $LRT_{2p-H_0} > t_{.95}$. This is not a circular definition; $t_{.95}$ is computed from the behaviour of simulated LRT at points outside as well as inside N_{10} for each site, while for $(\beta_0, \sigma_0, \tau_0)$ within N_{10} and even at $(\hat{\beta}, \hat{\sigma}, \hat{\tau})$ simulation may, if N_{10} is inappropriate, give LRT^* with 95th percentile > 10 .

Profile Likelihood Confidence Intervals for $ERR_{1,\phi}$ and $ERR_{0.025,\phi}$ are then constructed using all three estimates for the critical value. With ϕ fixed, let U_ϕ be the set of those $(\beta_0, \sigma_0, \tau_0)$ which cannot be ruled out with 95% confidence as $LRT_{2p-H_0} < t_{.95}$ (alternatively $< t'_{.95}$, or $< t''_{.95}$) Define the 95%CI for $ERR_{D,\phi}$ as the range of $ERR_{D,\phi}$ over U_ϕ .

When $\sigma_0 = 0$, LRT_{lin-H_0} is the Likelihood Ratio Test for the hypothesis $H_0: \beta = \beta_0$ and $\sigma = 0$ vs. the alternative $\beta \neq \beta_0$ and $\sigma = 0$, while LRT_{2p-lin} is the Likelihood Ratio Test for the hypothesis $\sigma = 0$ vs. the alternative $\sigma \neq 0$. Note $LRT_{2p-lin} + LRT_{lin-H_0} = LRT_{2p-H_0}$. Simulated null distributions of all three LRT's are obtained for points with $\sigma = 0$. Conservative, global, and refined estimates $T_{.95}$, $T'_{.95}$ and $T''_{.95}$ of the 95% critical value for LRT_{2p-lin} are then defined in the same fashion as $t_{.95}$, $t'_{.95}$ and $t''_{.95}$ for LRT_{2p-H_0} . For each cancer, $T'_{.95}$ is the supremum of the 95th percentiles of γ distributions fitted to the simulations of LRT_{2p-lin} , $T'_{.95}$ is the supremum of 95th percentiles of the fitted γ distributions and simulations of LRT_{2p-lin} , and $T_{.95}$ is an overall conservative value exceeding $T'_{.95}$ for all cancer sites considered. Likewise $T'_{.99}$ and $T''_{.99}$ are defined from the 99th and 99.9th percentiles of the fitted γ distributions. These various estimates are used as critical values for LRT_{2p-lin} when testing the linear model against the two-phase model, given the observed data.

Latency

For latency $\phi = 5, 6, \dots, 44$ BC_a 95%CIs for $ERR_{1,\phi}$ and $ERR_{0.025,\phi}$ are computed.

Since the observed data is regarded as a sample from an underlying distribution, the optimal latency ϕ_m as inferred from the data is an estimate, whose distribution is again obtained by simulation. The two-phase model is fitted at ϕ_m and the fitted model is resampled to provide simulated data, from which a new estimate $\tilde{\phi}_m$ is determined. To simplify, $\tilde{\phi}_m$ is restricted to integer values 5, 6, ... 44. The process is repeated $\times 200$ for the stomach, liver, lung, pancreas and leukaemia. The resulting set of $\tilde{\phi}_m$ is compared with the range of latencies for which BC_a 95% CIs are strictly positive, and likewise with the range for which LRT_{2p-lin} exceeds the estimated critical values.

To test whether the distributions of LRT_{2p-con} and LRT_{2p-lin} depend on latency, null distributions at $(\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$ are simulated ($\times 500$) for the stomach with $\phi = 5, 10, 15, \dots, 40$ and compared with the null distribution from simulation ($\times 1000$) at ϕ_m .

City, dose range, and gender

The models are refitted with “city” as an added control covariate. For each of the 5 cancers, the optimal latency Φ_m (restricted to 5, 6, ... 44) is determined along with latency ranges over which BC_a 95% and 90% CIs for ERR_1 are strictly positive.

The models including “city” are fitted to the 5 - 500 mSv subcohort. A limited analysis of the null distributions of LRT_{2p-con} and LRT_{2p-lin} including “city” is carried out on the 0 - 20 mSv and 5 - 500 mSv dose ranges. For each cancer at its Φ_m , $H_0: (\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$ is used for simulation of LRT_{2p-con} and $H_0: (\beta_0, \sigma_0, \tau_0) = (\hat{\beta}_{lin}, 0, \text{arbitrary})$ where $\hat{\beta}_{lin}$ is the fitted parameter for the linear model, is used for simulation of LRT_{2p-lin} . Gamma distributions fitted to the simulated LRT^* are used to estimate 95% critical values and to assign p-values to the LRT_{2p-con} and LRT_{2p-lin} arising from the observed data.

The models including “city” are fitted separately to the male and female subcohorts in the 0 - 20 mSv dose range for the stomach, liver, and lung.

Finally, the linear model including “city” is fitted to the 0 - 5 mSv, 5 - 20 mSv, 0 - 0.5 mSv, and 0.5 - 20 mSv data for the liver and lung.

The very extensive simulations of LRT were shared across a number of PC's.

Results

Table 1 shows the individual cancer sites with over 100 cases (deaths) in the subcohort.

To check **R** against Excel, the two-phase model is fitted to the stomach data for latencies $\phi = 5, 6, \dots, 44$ and $LRT_{2p-con,\phi}$ computed in both programmes. The difference $(LRT_{2p-con,\phi,R}) - (LRT_{2p-con,\phi,Excel})$ has a range of (-0.079, 0.000), mean = -0.004, s.d. = 0.014. At the optimal latency $\phi_m = \phi_{mabs} = 11.89$, $LRT_{2p-con,\phi} = 21.1903$ by either method. The parameter estimates in **R** are $\hat{\beta} = 0.4586$, $\hat{\sigma} = 120.0076$, $\hat{\tau} = 82.6729$, confirming the point estimates reported in [2]. On that basis, the methods are taken as comparable. Results are also comparable when computing LRT-based confidence intervals.

For the linear model $ERR = \beta D_\phi$ with $\phi = 5, 6, \dots, 44$ only the liver and urinary tract showed significant results.

Table 1: Cancer sites with over 100 cases (deaths) in the 0-20 mSv subcohort

Site	Cases (deaths) in the 0-20 mSv subcohort
Stomach	1482
Liver	540
Lung	524
Pancreas	179
Rectum	171
Oesophagus	131
Gall	125
Lymph	109
Leukaemia	105
Breast (F)	105
Urinary	103

Figure 1 shows $LRT_{lin-con,\varphi}$ against φ for these two cancers, while Figure 2 shows the fitted values $ERR_1 = \hat{\beta}$ when $\varphi \geq 30$ with 95% CIs (Profile Likelihood, assuming $LRT \sim \chi^2$ on 1 d.f. for testing $\beta = \beta_0$ against $\beta \neq \beta_0$). For the liver with this model, $\varphi_m = \varphi_{mabs} = 38.58$, at which $\hat{\beta} = 0.69$ (0.25, 1.26). Of the 540 cases in the subcohort, 171 have $\varphi > 38.58$. For the urinary tract, φ is locally optimal at 41.32 at which $\hat{\beta} = 2.14$ (0.51, 5.12). Of the 103 cases in the subcohort, 23 have $\varphi > 41.32$.

The stomach, liver, lung, pancreas, and leukaemia were selected for further analysis as $LRT_{2p-lin,\varphi} > 6$ for some φ , an indication that the dose response may be non-linear. For the pancreas and leukaemia, Figure 3 shows $LRT_{2p-lin,\varphi}$ and $LRT_{2p-con,\varphi}$ while Figure 4 shows $ERR_{1,\varphi} = \hat{\beta} + \hat{\sigma} \exp(-\hat{\tau})$ as estimated from fitting the two-phase model at latency φ . Note that $\hat{\beta}$ may differ greatly from the value obtained by fitting the linear model at φ . Related graphs




Figure 1
LRT for Linear vs. Control model: liver and urinary. For cancers of the liver (blue) and urinary (red) and for latency $\varphi = 5, 6, \dots, 44$ years, $LRT = LRT_{lin-con,\varphi}$ is the Likelihood Ratio Test for comparing the linear and control models at latency φ . Values above the horizontal line $LRT = 3.841$ are significant at $p < 0.05$.




Figure 2
ERR₁ with 95% CIs for Linear model: liver and urinary. For cancers of the liver (blue) and urinary (red) and for latency $\varphi = 30, 31, \dots, 44$ years, ERR_1 is the Excess Relative Risk from 10 mSv (lagged dose) as estimated by fitting the linear model at latency φ . The error bars show Profile Likelihood 95% CIs assuming a χ^2 (1 d.f.) distribution of LRT for testing $\beta = \beta_0$ against $\beta \neq \beta_0$.

for the stomach, liver, and lung were shown in [2], though their statistical significance is reconsidered below.

Table 2 shows the latencies φ_{mabs} and φ_m which maximise $LRT_{2p-con,\varphi}$ without and with the constraint $ERR_{1,\varphi} \geq 0$, the values of $LRT_{2p-con,\varphi}$ and $LRT_{2p-lin,\varphi}$ at φ_m along with the fitted parameters and corresponding point estimates of ERR_1 and $ERR_{0.025}$ and their bootstrap




Figure 3
LRT for Two-phase vs Control and Linear models: pancreas and leukaemia. For each cancer and for latency $\varphi = 5, 6, \dots, 44$ years, $LRT_{2p-con} = LRT_{2p-con,\varphi}$ is the Likelihood Ratio Test for comparing the two-phase and control models at latency φ , and $LRT_{2p-lin} = LRT_{2p-lin,\varphi}$ is the Likelihood Ratio Test for comparing the two-phase and linear models at latency φ .




Figure 4
ERR₁ for Two-phase model: pancreas and leukaemia.
 For cancers of the pancreas (red) and leukaemia (blue) and for latency $\phi = 5, 6, \dots, 44$ years, ERR₁ is the Excess Relative Risk from 10 mSv (lagged dose) as estimated by fitting the two-phase model at latency ϕ .

confidence intervals by the BC_a (5000 replications) and percentile (1000 replications) methods. For the stomach, liver, and lung, these confirm the point estimates in [2].

Coverage for the BC_a method is estimated for the stomach at 94% for ERR₁ (376 of 400) and 93% for ERR_{0.025} (372 of 400). Coverage for the percentile method is estimated for the stomach using the 0 - 20 mSv Hiroshima subcohort with the simplified two-phase model (10 year age-at-exposure categories) giving 94.3% for ERR₁ (377 of 400) and 93% for ERR_{0.025} (372 of 400). All CIs reported in Table 2 use the full model (5 year categories, both cities).

For the stomach with latency $\phi = 5, 6, \dots, 21$, Figure 5 shows the BC_a 95% confidence intervals (B = 5000) for ERR₁ and ERR_{0.025}. Each of these CIs is strictly positive. Since the minimum time-since-exposure in the subcohort is 6.08 years, for $\phi = 5$ or 6 the model involves no correction for latency and ERR is a function of the unmodified colon dose.

More generally, for each site (stomach, liver, lung, pancreas, leukaemia) there is a neighbourhood surrounding ϕ_m over which BC_a 95% CIs for ERR₁ and ERR_{0.025} are strictly positive, which was evaluated restricting to integer latencies and using B = 5000 bootstrap replications. For the stomach, both CIs are

Table 2: Latencies, LRT, fitted parameters, ERR and bootstrap confidence intervals for the two-phase model

Site	ϕ_{mabs}	ϕ_m	LRT_{2p-con, ϕ_m}	LRT_{2p-lin, ϕ_m}	$\hat{\beta}$	$\hat{\sigma}$	$\hat{\tau}$	ERR ₁	ERR _{0.025}
Stom	11.89	11.89	21.19	19.64	0.46	120.01	82.67	0.46 (0.21, 0.80) ^{bca} (0.19, 0.79) ^{per}	0.39 (0.15, 0.70) ^{bca} (0.15, 0.71) ^{per}
Liver	36.90	36.90	34.87	27.64	1.43	291.22	76.76	1.43 (0.70, 2.41) ^{bca} (0.72, 2.39) ^{per}	1.10 (0.49, 1.90) ^{bca} (0.40, 1.88) ^{per}
Lung	36.99	13.60	16.04	14.74	0.44	37.90	4.46	0.88 (0.34, 1.50) ^{bca} (0.27, 2.07) ^{per}	0.86 (0.40, 1.49) ^{bca} (0.32, 2.02) ^{per}
Panc	11.86	11.86	16.22	14.80	9.77	1060.94	43.77	9.77 (3.50 ^a , 14.27) ^{bca} (1.72, 55.11) ^{per}	9.12 (3.25 ^b , 13.46) ^{bca} (1.49, 48.25) ^{per}
Leuk	23.66	23.66	25.40	25.29	1.69	3353.15	172.25	1.69 (0.20, 4.81) ^{bca} (0.19, 4.77) ^{per}	1.17 (0.18, 3.58) ^{bca} (0.24, 3.79) ^{per}

ϕ_{mabs} : latency (years) which maximises LRT_{2p-con}
 ϕ_m : optimal latency, which maximises LRT_{2p-con} with the constraint $ERR_1 \geq 0$
 LRT_{2p-con, ϕ_m} : Likelihood Ratio Test for the two-phase model against the control model at ϕ_m
 LRT_{2p-lin, ϕ_m} : Likelihood Ratio Test for the two-phase model against the linear model at ϕ_m
 $\hat{\beta}, \hat{\sigma}, \hat{\tau}$: fitted parameters for the two-phase model at ϕ_m
 ERR₁: Excess Relative Risk at 10 mSv (lagged by ϕ_m), as estimated from the fitted two-phase model
 ERR_{0.025}: Excess Relative Risk at 0.25 mSv (lagged by ϕ_m), as estimated from the fitted two-phase model
^{bca}: Bootstrap BC_a 95%CI (5000 bootstrap replications)
^{per}: Bootstrap percentile 95%CI (1000 bootstrap replications)
^a: minimum bootstrap value, lower tail probability = 0.034
^b: minimum bootstrap value, lower tail probability = 0.024




Figure 5
ERR₁ and ERR_{0.025} with 95% CIs for Two-phase model: stomach. For stomach cancers and for latency $\varphi = 5, 6, \dots, 21$ years, ERR₁ (red) is the Excess Relative Risk from 10 mSv (lagged dose) as estimated by fitting the two-phase model at latency φ , while ERR_{0.025} (green) is the Excess Relative Risk from 0.25 mSv (lagged dose) as estimated by fitting the two-phase model at latency φ . The error bars show bootstrap 95% CIs computed with the BC_a method, using 5000 replications.

strictly positive when $5 \leq \varphi \leq 21$. For the liver, both CIs are strictly positive when $32 \leq \varphi \leq 43$. For the lung, both CIs are strictly positive when $7 \leq \varphi \leq 21$. For the pancreas, both CIs are strictly positive when $5 \leq \varphi \leq 11$. For leukaemia, the 95% CI for ERR₁ is strictly positive when $24 \leq \varphi \leq 26$, but the 95% CI for ERR_{0.025} is strictly positive when $19 \leq \varphi \leq 36$.

For each site, simulating data (200 sets) from the fitted model at φ_m and re-determining the optimal latency $\tilde{\varphi}_m$ (restricting to integer values) from the simulated data shows the uncertainty in φ_m itself. For the stomach $5 \leq \tilde{\varphi}_m \leq 21$ for 196 out of 200 simulated datasets, while $5 \leq \tilde{\varphi}_{mabs} \leq 21$ for 187 out of 200 simulated datasets. For the liver, $32 \leq \tilde{\varphi}_m \leq 43$ for 200 out of 200 simulated datasets, while $32 \leq \tilde{\varphi}_{mabs} \leq 43$ for 197 out of 200

simulated datasets. For the lung, $7 \leq \tilde{\varphi}_m \leq 21$ for 184 of 200, while $7 \leq \tilde{\varphi}_{mabs} \leq 21$ for 173 of 200 simulated datasets (nb for the lung $\varphi_m \neq \varphi_{mabs}$). For the pancreas the results are weaker, as $5 \leq \tilde{\varphi}_m \leq 11$ for 157 of 200, and $5 \leq \tilde{\varphi}_{mabs} \leq 11$ for 151 of 200 simulated datasets. For leukaemia $24 \leq \tilde{\varphi}_m \leq 26$ for 132 of 200 and $24 \leq \tilde{\varphi}_{mabs} \leq 26$ for 130 of 200, but $19 \leq \tilde{\varphi}_m \leq 36$ for 188 of 200 and $19 \leq \tilde{\varphi}_{mabs} \leq 36$ for 184 of 200 simulated datasets.

Additional File 1, Tables S1, S2, and S3 give the simulated null distributions of LRT for the two-phase model with the null hypothesis $H_0: (\beta, \sigma, \tau) = (\beta_0, \sigma_0, \tau_0)$ vs the alternative $(\beta, \sigma, \tau) \neq (\beta_0, \sigma_0, \tau_0)$, for the stomach, liver, lung, pancreas, and leukaemia. Additional File 1, Table S1 shows simulation for each cancer at the fitted values $(\beta_0, \sigma_0, \tau_0) = (\hat{\beta}, \hat{\sigma}, \hat{\tau})$ and for randomly selected points in the neighbourhood N_{10} of the fitted values (see Methods). Additional File 1, Table S2 shows simulation for each cancer with $\sigma_0 = 0$, where τ_0 is arbitrary. Additional File 1, Table S3 shows additional simulation for the stomach when $\sigma_0 \neq 0$, but $(\beta_0, \sigma_0, \tau_0)$ is outside the neighbourhood N_{10} . For the simulations in S2, Additional File 1, Table S4 shows the results for the linear model and the comparison with the two-phase model. These simulations are carried out at the optimal latency for the specific cancer.

As the control parameters are optimised subject to H_0 before simulating LRT, perhaps other choices of control parameters while retaining H_0 might yield different estimates of the null distribution of LRT subject to H_0 . However, four sets of simulations ($\times 500$) for the stomach with $(\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$ using very different choices of control parameters and total cases expected, yielded fairly similar LRT* and fitted gamma distributions as shown in Table 3. Optimised control parameters for the observed data are shown in the last row. This is evidence that the null distribution of LRT_{2p-H_0} is approximately independent of the parameters used to simulate the data, provided that H_0 holds. In the terminology of [7] (Chapter 4 p. 139)

Table 3: Null distribution of LRT_{2p-con} for the stomach with various control parameters

α	β_1	β_2	β_3	β_4	β_5	β_6	β_7	β_8	β_9	β_{10}	β_{11}	β_{12}	β_{13}	β_{14}	β_{15}	β_{16}	N	qlrt	s	r	qgam	expect
-5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	500	8.23	2.38	0.64	8.32	11389.77
-15	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	500	8.61	2.36	0.63	8.50	7528.62
-8	-1	0	2	0	0	0	0	5	0	0	0	0	0	0	0	0	500	8.39	2.35	0.63	8.42	1418.11
-14	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	500	8.45	2.24	0.60	8.59	1013.12
-18.13	-0.84	3.11	-1.05	-0.77	-1.09	-0.69	-0.27	-0.31	-0.29	0.20	0.15	0.29	0.40	0.37	0.45	0.16	1000	8.88	2.42	0.60	8.96	1482.00

α, β_j : specified values of control parameters

N: number of simulations

qlrt: 95th percentile of LRT_{2p-con}^*

s, r: shape and rate parameters of the fitted gamma distribution for LRT_{2p-con}^*

qgam: 95th percentile of the fitted gamma distribution for LRT_{2p-con}^*

expect: expected number of cases

Table 4: Profile Likelihood 95% confidence intervals for ERR at estimated critical values of LRT_{2p-H_0}

site	φ_m	$t_{.95}$	ERR ₁	ERR _{0.025}	$t'_{.95}$	ERR ₁	ERR _{0.025}	$t''_{.95}$	ERR ₁	ERR _{0.025}
stom	11.89	10	(0.08,1.02)	(0.06,0.93)	9.72	(0.08,1.01)	(0.06,0.92)	8.16	(0.11,0.95)	(0.08,0.87)
liver	36.90	10	(0.38,3.21)	(0.19,2.59)	8.59	(0.44,3.05)	(0.23,2.45)	8.28	(0.46,3.01)	(0.25,2.42)
lung	13.60	10	(0.07,3.89)	(0.08,3.87)	9.44	(0.08,3.75)	(0.10,3.74)	8.48	(0.11,3.52)	(0.12,3.50)
panc	11.86	10	(0.48,-)	(0.38,-)	9.03	(0.60,-)	(0.49,-)	8.79	(0.64,-)	(0.52,-)
leuk	23.66	10	(-0.21,8.20)	(0.03,6.46)	7.93	(-0.09,7.05)	(0.06,5.51)	7.58	(-0.07,6.86)	(0.06,5.35)

$t_{.95}$, $t'_{.95}$ and $t''_{.95}$: conservative, global and refined estimates of the 95% critical value of LRT for the hypothesis $H_0: (\beta, \sigma, \tau) = (\beta_0, \sigma_0, \tau_0)$ vs. the alternative $(\beta, \sigma, \tau) \neq (\beta_0, \sigma_0, \tau_0)$. See Methods.

LRT_{2p-con}^* is an “approximate pivot” even though Wilks Theorem fails. In turn, this gives the basis for rejecting H_0 given the observed data.

The simulated null distributions of LRT_{2p-H_0} from Additional File 1, Tables S1, S2, and S3 are then applied to estimate $t_{.95}$, $t'_{.95}$ and $t''_{.95}$ as defined in Methods. All simulations showed LRT and its fitted gamma distribution had 95th percentiles $qlrt(0.95) < 10$ and $qgamma(0.95) < 10$. Thus $t_{.95} = 10$ is a conservative estimate throughout the parameter space, for all cancer sites considered here, and the choice of N_{10} is appropriate (see Methods).

Table 4 shows Profile Likelihood 95% confidence intervals for ERR_1 and $ERR_{0.025}$ at optimal latency φ_m as computed with the various estimated critical values.

Likewise from Additional File 1, Table S4 and using the notation in that file, all simulations of the null distribution of LRT_{2p-lin} showed $qlrt2(0.95) < 8$ and $qgamma2(0.95) < 8$ so $T_{.95} = 8$ is a conservative estimate throughout the parameter space, for all cancer sites considered here. For any given site $T'_{.95}$ is the supremum of $qlrt2(0.95)$ and $qgamma2(0.95)$ over simulations for that site. $T''_{.95}$ is the supremum of $qgamma2(0.95)$ over simulations for that site. Likewise $T''_{.99}$ and $T''_{.999}$ are the suprema of $qgamma2(0.99)$ and $qgamma2(0.999)$ over simulations for that site. Table 5 shows these critical values and the observed value of LRT_{2p-lin} (see Table 2) for each site.

Table 5: Critical values and observed value of LRT_{2p-lin}

Site	φ_m	$T_{.95}$	$T'_{.95}$	$T''_{.95}$	$T''_{.99}$	$T''_{.999}$	LRT_{2p-lin}
Stom	11.89	8	7.542	7.276	10.394	14.708	19.64
Liver	36.90	8	6.779	6.603	9.329	13.082	27.64
Lung	13.60	8	7.418	6.930	9.795	13.740	14.74
Panc	11.86	8	7.372	7.007	10.049	14.265	14.80
Leuk	23.66	8	6.269	5.832	8.507	12.245	25.29

$T_{.95}$, $T'_{.95}$, $T''_{.95}$: conservative, global and refined estimates of the 95% critical value of LRT for comparison of two-phase and linear models. See Methods.

$T''_{.99}$, $T''_{.999}$: refined estimates of the 99% and 99.9% critical value of LRT for comparison of two-phase and linear models. See Methods.

LRT_{2p-lin} : observed value of LRT for comparison of two-phase and linear models. See Table 2.

Null distributions of LRT_{2p-H_0} and LRT_{2p-lin} for the stomach with $\varphi = 5, 10, \dots, 40$ show little variation with latency and are similar to those obtained at φ_m as shown in Table 6.

Simulation of the optimal latency $\tilde{\varphi}_m$ as described earlier also has implications for non-linearity. Again restricting to integral latencies, for the stomach $LRT_{2p-lin} > 9.4$ when $5 \leq \varphi \leq 21$ and 196 of 200 simulated datasets gave $\tilde{\varphi}_m$ in this range. For the liver $LRT_{2p-lin} > 16.7$ when $34 \leq \varphi \leq 38$ (198 of 200 simulations). For the lung $LRT_{2p-lin} > 7.7$ when $7 \leq \varphi \leq 21$ (184 of 200 simulations). For leukaemia $LRT_{2p-lin} > 9.4$ when $17 \leq \varphi \leq 36$ (191 of 200 simulations). Each of these results shows non-linearity (see Table 5) and for the stomach and liver the evidence is very strong. For the pancreas, $LRT_{2p-lin} > 9.5$ when $7 \leq \varphi \leq 11$ but only 156 of 200 simulations give $\tilde{\varphi}_m$ in this range.

The covariate “city” has little impact on the estimates of ERR when taken as an additional control. For the liver including “city”, BC_a 95% CIs for ERR_1 and $ERR_{0.025}$ are strictly positive when $29 \leq \varphi \leq 43$, again restricting to integral latencies. With “city” included in both models LRT_{2p-con} attains its maximum subject to $ERR_1 \geq 0$ when $\varphi_m = 37$ and $LRT_{2p-con} = 28.41$. At $\varphi_m = 37$, $ERR_1 = 1.26$ with BC_a 95%CI (0.61, 2.14) and $ERR_{0.025} = 0.68$ with BC_a 95%CI (0.18, 1.25). For comparison, without “city” the optimal integral latency is $\varphi_m = 37$, at which $ERR_1 = 1.22$ with BC_a 95%CI (0.59, 2.11) and $ERR_{0.025} = 0.74$ with BC_a 95%CI (0.23, 1.43). As a test of non-linearity (with “city” included in both models) $LRT_{2p-lin} > 6.8$

Table 6: LRT simulations for the stomach with $(\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$ and various latencies

φ	N	qlrt2pcon	s	r	qgam2pcon	qlrt2plin	sl	rl	qgam2plin
5	500	9.53	2.39 (0.14)	0.59 (0.04)	9.26	7.72	2.07 (0.12)	0.66 (0.04)	7.39
10	500	8.79	2.56 (0.15)	0.65 (0.04)	8.67	6.87	2.09 (0.12)	0.70 (0.05)	7.02
15	500	8.90	2.46 (0.15)	0.64 (0.04)	8.59	6.89	2.02 (0.12)	0.72 (0.05)	6.63
20	500	8.21	2.38 (0.14)	0.63 (0.04)	8.48	6.87	2.00 (0.12)	0.72 (0.05)	6.60
25	500	8.70	2.62 (0.16)	0.65 (0.04)	8.84	7.58	2.01 (0.12)	0.66 (0.04)	7.20
30	500	8.51	2.31 (0.14)	0.63 (0.04)	8.28	6.71	1.84 (0.11)	0.68 (0.05)	6.62
35	500	8.84	2.31 (0.14)	0.61 (0.04)	8.54	7.09	1.79 (0.10)	0.65 (0.04)	6.79
40	500	8.46	2.45 (0.15)	0.67 (0.04)	8.11	6.95	1.86 (0.11)	0.70 (0.05)	6.46
11.89	1000	8.88	2.42 (0.10)	0.60 (0.03)	8.96	7.18	1.94 (0.08)	0.65 (0.03)	7.10

φ : latency
 N: number of simulations
 qlrt2pcon: 95th percentile of $LRT_{2p-H_0}^*$
 s, r: shape and rate parameters with their estimated standard errors for the fitted gamma distribution for $LRT_{2p-H_0}^*$
 qgam2pcon: 95th percentile of the fitted gamma distribution for $LRT_{2p-H_0}^*$
 qlrt2plin: 95th percentile of LRT_{2p-lin}^*
 sl, rl: shape and rate parameters with their estimated standard errors for the fitted gamma distribution for LRT_{2p-lin}^*
 qgam2plin: 95th percentile of the fitted gamma distribution for LRT_{2p-lin}^*

when $29 \leq \varphi \leq 41$, and $LRT_{2p-lin} > 18.15$ when $34 \leq \varphi \leq 38$, whereas without “city” $LRT_{2p-lin} > 6.86$ when $32 \leq \varphi \leq 41$ and $LRT_{2p-lin} > 16.73$ when $34 \leq \varphi \leq 38$.

Table 7 includes results with “city” for the 0 - 20 mSv dose range, for all 5 cancers. It also shows that fitting the two-phase model with “city” to the 0 - 20 mSv and 5 - 500 mSv dose ranges gives comparable results for ERR_1 and latency, for the stomach, liver, lung, and leukaemia.

A limited analysis by simulation of LRT for the model with “city” was carried out over the 0 - 20 mSv and 5 - 500 mSv dose ranges, focused at the optimal (integral) latencies on the null distributions of LRT_{2p-con} and LRT_{2p-lin} at $(\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$ and $(\beta_0, \sigma_0, \tau_0) = (\hat{\beta}_{lin}, 0, \text{arbitrary})$ where $\hat{\beta}_{lin}$ is obtained by fitting the linear model. Results are shown in Table 8 and the fitted gamma distributions are used to assign p-values to the observed LRT in Table 7.

From Table 8 (with “city”) and Additional File 1, Table S4 (without “city”), the criterion $LRT_{2p-lin} > 6$ is a test of non-linearity at 90% level. Accordingly, Table 7 also shows the latency ranges surrounding Φ_m for which $LRT_{2p-lin} > 6$.

Other aspects of the analysis (simulated null distributions of LRT_{2p-con} and LRT_{2p-lin} across the parameter space and simulated variation in optimal latency φ_m) were not repeated with “city”.

For the stomach, liver, and lung Table 9 shows the results when the two-phase model with “city” is fitted separately to the male and female 0 - 20 mSv subcohorts. For the pancreas and leukaemia, there were too few cases to split the data by gender.

Table 10 shows the linear model with “city” fitted to the 0 - 20 mSv, 0 - 5 mSv, 5 - 20 mSv, 0 - 0.5 mSv, and 0.5 - 20 mSv subcohorts for the liver and lung.

Discussion

This paper develops and partially corrects the approach in [2] and the two should be read in conjunction. I focus initially on the 0 - 20 mSv dose range, which provides over 60% of the person-years of observation in the Life Span Study 12 cohort. Over the full data range 0 - 8000 mSv and the truncated range 0 - 4000 mSv the dose response for cancer mortality is known to be approximately linear and risk estimates for 1000 mSv have been obtained through the ongoing Life Span Study project. The ICRP recommendations for radiation protection are then based on linear extrapolation, as the Excess Relative Risk from 10 mSv is presumed to be 0.01 times the ERR from 1000 mSv.

If we were confident that the approximate linearity of the dose response extends to the low dose region, then linear extrapolation would be justified. But this is not known, and the response may be approximately linear over a

Table 7: Optimal (integral) latency, LRT and ERR, including “city”, by dose range

Dose range	Site	Φ_m	LRT _{2p-con} at Φ_m	LRT _{2p-lin} at Φ_m	ERR ₁ at Φ_m	Latency Range	ERR _{0.025} at Φ_m	Latency Range
0-20	Stom	11	13.02 p = 0.007	12.27 p = 0.003	0.38 (0.11, 0.70) (0.16, 0.65)*	5-18 5-21* 9-21 ^{nl}	0.34 (0.11, 0.63) (0.14, 0.59)*	5-21 5-21*
5-500	Stom	8	9.03 p = 0.025	5.74 p = 0.07	0.29 (0.06, 0.60) (0.09, 0.55)*	7-9 5-11*		
0-20	Liver	37	28.41 p < 10 ⁻⁷	18.96 p < 10 ⁻⁴	1.26 (0.61, 2.14) (0.69, 1.97)*	29-43 29-43* 29-41 ^{nl}	0.68 (0.18, 1.25) (0.24, 1.20)*	29-44 29-44*
5-500	Liver	37	14.47 p = 0.003	10.55 p = 0.005	0.74 (0.25, 1.43) (0.32, 1.30)*	34-41 34-42* 34-41 ^{nl}		
0-20	Lung	16	10.43 p = 0.03	7.13 p = 0.05	1.00 (0.36, 1.84) (0.42, 1.72)*	10-21 10-21* 12-16 ^{nl}	0.80 (0.21, 1.66) (0.28, 1.53)*	10-16 10-21*
5-500	Lung	16	21.69 p < 10 ⁻⁴	19.63 p < 10 ⁻⁵	1.33 (0.67, 2.22) (0.73, 2.10)*	7-21 7-21* 12-21 ^{nl}		
0-20	Panc	10	14.89 p = 0.002	13.7 p < 0.001	11.32 (5.35, 16.46) (5.44, 15.60)*	5-11 5-11* 7-11 ^{nl}	10.77 (4.21, 16.05) (4.70, 15.31)*	5-11 5-11*
5-500	Panc	42	1.97 p = 0.64	1.96 p = 0.38	0.44 (-, -)	-		
0-20	Leuk	25	21.66 p < 10 ⁻⁴	21.66 p < 10 ⁻⁵	1.39 (0.09, 4.31) (0.26, 3.79)*	24-25 24-26* 17-36 ^{nl}	0.89 (0.11, 2.22) (0.16, 2.16)*	19-33 17-33*
5-500	Leuk	28	14.76 p < 0.001	8.60 p = 0.013	1.83 (0.45, 3.92) (0.59, 3.66)*	24-31 24-32* 24-28 ^{nl}		

Dose range: data on which the two-phase model is fitted, including “city” as a control covariate
 Φ_m : latency, restricted to integers 5, 6,... 44, which maximises LRT_{2p-con} subject to ERR₁ ≥ 0
 LRT_{2p-con}: Likelihood Ratio Test comparison of two-phase and control models at Φ_m . p values derived from Table 8
 LRT_{2p-lin}: Likelihood Ratio Test comparison of two-phase and linear models at Φ_m . p values derived from Table 8
 ERR₁: Excess Relative Risk at 10 mSv, from the two-phase model fitted across the dose range with latency Φ_m , and its BC_a 95%CI (5000 replications)
 Latency range: integral latency range around Φ_m for which BC_a 95%CI is strictly positive
 *: BC_a 90%CI (5000 replications)
^{nl}: integral latency range around Φ_m for which LRT_{2p-lin} > 6
 ERR_{0.025}: as above, for 0.25 mSv (computed only when Dose range = 0-20 mSv)

wide dose range but highly non-linear at lower doses. There are many examples of non-linear dose response in radiation cell biology [16,17].

Thus, if the Japanese data is used to derive risk estimates for doses such as 10 mSv or 1mSv which are directly relevant to occupational and public exposure, it makes sense to consider the 0 - 20 mSv data in its own right and in relation to wider dose ranges, rather than to pool the data and apply linear extrapolation.

Secondly, a latency parameter ϕ is used to assess the delay between exposure and cancer mortality. Although

it would be better to allow latency to modify dose by some smooth function rather than an abrupt switch from no effect to full effect when Time-Since-Exposure passes ϕ , this is much harder to compute and was not attempted here.

As pointed out during peer review, we should consider at the outset whether the data is sufficient for fitting a non-linear model based on mean dose. Figure 6 shows scatterplots of p-y observation against mean dose, for the ranges 0 - 500 mSv, 5 - 20 mSv, 0 - 5 mSv, and 0 - 0.5 mSv. Clearly the 0 - 500 mSv and 5 - 500 mSv data contains a wide variety of doses. The 5 - 20 mSv data shows a

Table 8: simulated null distribution of LRT_{2p-con} and LRT_{2p-lin} including “city”, by dose range

Dose range	Site	Φ_m	LRT_{2p-con} Shape	LRT_{2p-con} Rate	$t_{0.95}$	LRT_{2p-lin} shape	LRT_{2p-lin} rate	$T_{0.95}$
0-20	Stom	11	2.38	0.59	9.06	1.98	0.65	7.25
5-500	Stom	8	2.03	0.62	7.72	1.30	0.55	6.42
0-20	Liver	37	2.50	0.73	7.63	1.69	0.64	6.58
5-500	Liver	37	1.62	0.49	8.39	1.14	0.53	6.16
0-20	Lung	16	2.47	0.58	9.43	2.09	0.68	7.20
5-500	Lung	16	1.81	0.61	7.26	1.38	0.66	5.58
0-20	Panc	10	2.35	0.61	8.65	2.13	0.71	6.93
5-500	Panc	42	1.72	0.52	8.18	1.18	0.60	5.61
0-20	Leuk	25	2.11	0.62	7.94	1.59	0.67	6.01
5-500	Leuk	28	1.87	0.62	7.34	1.25	0.56	6.14

gamma distributions are fitted to 500 simulations of LRT_{2p-con} for the null hypothesis $(\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$ and of LRT_{2p-lin} for the null hypothesis $(\beta_0, \sigma_0, \tau_0) = (\hat{\beta}_{lin}, 0, \text{arbitrary})$ where $\hat{\beta}_{lin}$ is the fitted parameter for the linear model. Models include “city” as a control covariate and are fitted at the optimal (integral) latency Φ_m for the site and dose range.

shape: shape parameter of the fitted gamma distribution

rate: rate parameter of the fitted gamma distribution

$t_{0.95}$: critical value of the fitted gamma distribution for LRT_{2p-con}^*

$T_{0.95}$: critical value of the fitted gamma distribution for LRT_{2p-lin}^*

Table 9: Male and Female subcohorts, with “city”, 0-20 mSv, integral latency

Sex	Site	Φ_{mabs}	Φ_m	LRT_{2p-con} at Φ_m	LRT_{2p-lin} at Φ_m	ERR_1 at Φ_m	Latency Range	$ERR_{0.025}$ at Φ_m	Latency Range
M	Stom	6	6	11.82	11.06	2.41 (1.24-3.52)	5-6 5-6 ^{nl}	2.30 (0.99-3.47)	5-6
F	Stom	10	10	12.26	10.67	0.57 (0.18-1.10)	9-13 9-18 ^{nl}	0.39 (0.07-0.56)	7-13
M	Liver	37	37	19.40	14.19	1.55 (0.58-3.05)	34-42 34-38 ^{nl}	1.00 (0.14-1.58)	34-42
F	Liver	20	36	10.90	8.82	1.01 (0.05-1.88)	34-38 27-36 ^{nl}	0.86 (0.04-1.38)	27-38
M	Lung	37	16	6.04	4.92	0.89 (0.16-2.00)	12-16	0.66 (0.09-1.93)	12-16
F	Lung	21	21	7.44	6.17	1.18 (0.41-2.28)	14-21 19-21 ^{nl}	0.95 (0.27-1.57)	14-21

notation as in Table 7

spread of mean doses. Whilst the 0 - 5 mSv data is concentrated below 1 mSv, there is a spread of mean doses in that region. Each dose range determines a very large dataset.

The fact that for the stomach, liver, lung, and leukaemia rather similar results for ERR_1 and latency are obtained from fitting the two-phase model across the 5 - 500 mSv dose range as from fitting across the 0 - 20 mSv dose range suggests that there is also sufficient information in the 0 - 20 mSv data to justify fitting this model. The stomach, with the largest number of cases, shows fairly tight confidence intervals for Excess Relative Risk over a broad range of latencies, which supports the validity of the model.

If the dose response were linear, similar estimates of its slope (β) should be obtained over different dose ranges. As the liver and lung data illustrate (Table 10), fitting the linear model separately to subcohorts of the 0 - 20 mSv dose range yields very different estimates of the dose response. For the liver, there are significant results at comparable latencies in the 0 - 20 mSv dose range and all the subranges, but the estimates of β from doses below 5 mSv (or below 0.5 mSv) are completely different from those obtained from doses above 5 mSv (or 0.5 mSv), in fact around 20 times higher when latency = 36 years. For the lung, the linear model detects some significant activity in restricted dose ranges, but the results are very different, and combining the two dose ranges yields insignificant results. By contrast, see Table 7, the two-phase model

Table 10: Linear model with “city” for liver and lung on partitions of 0-20 mSv, by latency

range p-y	Liver										Lung									
	0-20 mSv 1690392		0-5 mSv 1152356		5-20 mSv 538039		0-0.5 mSv 1141938		0.5-20 mSv 548454		0-20 mSv 1690392		0-5 mSv 1152356		5-20 mSv 538039		0-0.5 mSv 1141938		0.5-20 mSv 548454	
	LRT	β	LRT	β	LRT	β	LRT	β	LRT	β	LRT	β	LRT	β	LRT	β	LRT	β	LRT	β
6	0.01	-0.01	0.52	6.22	0.28	3.70	1.20	12.63	0.11	0.14	1.43	0.13	0.00	0.00	0.01	-0.14	0.00	0.00	0.17	0.18
7	0.02	-0.02	0.30	-2.00	0.05	-0.11	0.53	-4.57	0.00	0.01	1.40	0.13	0.10	2.23	0.00	-0.03	1.13	12.62	0.18	0.16
8	0.02	-0.02	0.30	-2.00	0.05	-0.11	0.53	-4.57	0.00	0.01	1.40	0.13	0.10	2.23	0.00	-0.03	1.13	12.62	0.18	0.16
9	0.01	-0.01	0.29	-2.00	0.01	-0.05	0.60	-4.71	0.00	0.02	1.29	0.12	0.00	0.00	0.08	-0.16	0.53	7.48	0.09	0.11
10	0.76	-0.08	1.02	-2.00	7.09	-0.50	3.04	-9.15	5.00	-0.46	1.63	0.14	0.13	2.45	0.35	0.37	1.66	14.30	0.69	0.31
11	0.75	-0.08	0.99	-2.00	7.06	-0.50	3.02	-9.12	4.96	-0.46	1.64	0.14	0.13	2.51	0.37	0.38	1.68	14.39	0.71	0.31
12	0.80	-0.09	1.18	-2.00	6.77	-0.50	3.81	-9.81	5.60	-0.47	2.15	0.16	0.81	6.90	1.98	0.95	3.55	22.14	2.11	0.57
13	0.79	-0.09	1.28	-2.00	6.70	-0.50	4.33	-10.24	5.48	-0.46	2.15	0.16	0.81	6.93	1.99	0.95	3.57	22.20	2.11	0.57
14	1.10	-0.10	2.52	-2.00	8.76	-0.50	14.14	-14.71	7.80	-0.50	3.29	0.20	0.07	1.69	7.75	2.31	2.42	14.89	6.46	1.15
15	1.10	-0.10	2.52	-2.00	8.40	-0.50	14.14	-14.71	7.83	-0.50	3.29	0.20	0.07	1.69	7.75	2.31	2.42	14.89	6.46	1.15
16	1.09	-0.10	2.49	-2.00	8.65	-0.50	14.08	-14.70	7.76	-0.50	3.30	0.20	0.08	1.77	7.81	2.32	2.45	15.00	6.51	1.15
17	0.94	-0.10	2.23	-2.00	8.11	-0.50	12.11	-14.38	7.63	-0.50	1.97	0.16	0.12	2.10	1.37	0.53	2.43	14.12	2.14	0.51
18	0.92	-0.10	2.21	-2.00	8.93	-0.56	11.96	-14.33	7.46	-0.51	1.98	0.16	0.12	2.15	1.40	0.54	2.46	14.24	2.17	0.52
19	0.89	-0.10	2.33	-2.00	9.31	-0.56	10.63	-14.12	8.27	-0.52	1.70	0.15	1.69	9.36	0.75	0.34	5.17	21.98	1.74	0.44
20	0.89	-0.10	2.33	-2.00	9.30	-0.56	10.63	-14.12	8.27	-0.52	1.70	0.15	1.69	9.36	0.75	0.34	5.17	21.98	1.74	0.44
21	0.88	-0.10	2.31	-2.00	9.86	-0.59	10.56	-14.10	8.20	-0.52	1.72	0.15	1.74	9.53	0.78	0.35	5.23	22.17	1.77	0.44
22	0.32	-0.06	1.75	-2.00	5.51	-0.50	7.84	-13.34	4.73	-0.44	0.68	0.09	0.04	1.04	0.18	-0.13	0.41	4.53	0.08	0.08
23	0.25	-0.05	1.89	-2.00	4.52	-0.47	8.88	-13.81	3.96	-0.41	0.58	0.09	0.05	1.15	0.40	-0.19	0.44	4.72	0.02	0.04
24	0.02	0.02	0.99	-2.00	0.49	-0.19	5.71	-12.83	0.52	-0.18	0.36	0.07	0.00	0.00	0.66	-0.22	0.22	3.13	0.00	0.00
25	0.02	0.02	0.99	-2.00	0.48	-0.19	5.71	-12.83	0.52	-0.18	0.36	0.07	0.00	0.00	0.66	-0.22	0.22	3.13	0.00	0.00
26	0.02	0.02	1.08	-2.00	0.46	-0.19	6.00	-13.00	0.50	-0.17	0.37	0.07	0.00	0.00	0.63	-0.22	0.23	3.25	0.00	0.00
27	0.38	0.08	0.27	-2.00	0.08	0.09	2.54	-9.59	0.03	0.05	0.35	0.07	0.82	-2.00	0.36	-0.17	0.29	-3.18	0.02	0.04
28	0.35	0.07	0.40	-2.00	0.07	0.08	2.89	-10.05	0.02	0.04	0.44	0.08	0.80	-2.00	0.16	-0.12	0.25	-2.98	0.12	0.10
29	1.18	0.15	0.00	0.00	1.29	0.40	0.41	-4.55	0.92	0.30	0.15	0.05	0.32	-2.00	0.68	-0.21	0.23	3.18	0.01	-0.02
30	1.19	0.15	0.00	0.00	1.30	0.40	0.41	-4.55	0.93	0.30	0.15	0.05	0.32	-2.00	0.67	-0.21	0.23	3.18	0.01	-0.02
31	1.21	0.15	0.00	0.00	1.35	0.41	0.39	-4.43	0.97	0.31	0.16	0.05	0.29	-2.00	0.63	-0.20	0.25	3.27	0.01	-0.02
32	1.42	0.17	0.00	0.00	1.27	0.38	0.16	3.36	0.85	0.28	0.14	0.05	0.40	-2.00	0.39	-0.16	0.00	0.00	0.00	0.01
33	1.29	0.16	0.00	0.00	1.10	0.35	0.19	3.61	0.71	0.25	0.09	0.04	0.35	-2.00	0.60	-0.19	0.00	0.00	0.01	-0.02
34	5.02	0.37	4.32	18.20	7.44	1.08	6.53	26.15	6.28	0.90	0.08	-0.04	0.24	-2.00	2.25	-0.31	0.00	0.00	0.84	-0.20
35	5.02	0.37	4.32	18.20	7.46	1.08	6.53	26.15	6.30	0.90	0.08	-0.04	0.24	-2.00	2.24	-0.31	0.00	0.00	0.84	-0.20
36	5.08	0.38	4.45	18.55	7.56	1.09	6.63	26.40	6.39	0.91	0.07	-0.04	0.24	-2.00	2.17	-0.31	0.00	0.00	0.80	-0.19
37	9.45	0.58	2.86	13.80	14.18	1.68	4.48	19.51	12.57	1.45	0.22	-0.07	0.42	-2.00	2.15	-0.30	0.13	-1.96	1.01	-0.21
38	8.62	0.56	3.15	14.53	12.94	1.54	4.85	20.35	11.46	1.33	0.16	-0.06	0.37	-2.00	1.84	-0.28	0.00	0.00	0.80	-0.19
39	9.61	0.71	1.20	8.11	10.39	1.18	1.28	9.11	9.75	1.09	0.26	-0.09	0.00	0.00	1.23	-0.24	0.13	2.12	0.64	-0.18
40	9.61	0.71	1.20	8.11	10.39	1.18	1.28	9.11	9.75	1.09	0.26	-0.09	0.00	0.00	1.23	-0.24	0.13	2.12	0.64	-0.18
41	9.74	0.71	1.28	8.39	10.56	1.19	1.33	9.33	9.91	1.11	0.24	-0.09	0.00	0.00	1.17	-0.23	0.14	2.24	0.60	-0.17
42	5.17	0.62	0.06	1.85	3.96	0.65	0.03	1.29	3.78	0.62	0.96	-0.22	1.12	6.72	2.12	-0.34	0.83	6.09	1.52	-0.29
43	4.18	0.55	0.07	1.93	2.96	0.55	0.03	1.29	2.81	0.53	0.92	-0.21	1.15	6.82	2.05	-0.33	0.83	6.09	1.45	-0.29
44	1.48	0.47	1.08	10.34	0.25	0.18	1.26	11.40	0.28	0.19	0.53	-0.25	0.15	3.14	0.85	-0.32	0.00	0.00	0.67	-0.29

range: dose range over which the linear model is fitted
 p-y: person-years for the dose range
 LRT: $LRT_{lin-con}$ when the linear model is fitted at latency ϕ . $LRT > 3.84$ indicates significance at $p < 0.05$
 β : fitted parameter value.

shows significant results for the lung with the 0 - 20 mSv data for latencies from 10 to 21 years.

It is not unusual for a model to achieve significance on portions of the data but fail to do so when they are combined. Even univariate Ordinary Least Squares regression on a bimodal independent variable may illustrate this, as in Figure 7 with synthetic data.

As discussed in [2] the graphs of ERR against latency show a clear separation into positive and negative

regions, as is also apparent with the linear model over restricted dose ranges for the liver and lung. For any given model, the “optimal latency” ϕ_m identifies the time lag which maximises LRT within the region of non-negative ERR_1 . The existence of a significant raised risk is of interest whether or not other latencies show significant decrease in risk, with possibly higher LRT. Frequently ϕ_m coincides with ϕ_{mabs} which maximises LRT without constraint, but the distinction is relevant for the lung (Table 2) and more generally when simulating the variation in latency.




Figure 6
p-y observation against mean dose. For the subcohorts 0-500 mSv, 5-20 mSv, 0-5 mSv, and 0-0.5 mSv, each data cell in the subcohort is represented by a vertical line at its mean dose, with height the p-y observation in the data cell. The total p-y observation for each subcohort is also shown.




Figure 7
Ordinary Least Squares fitting to (synthetic) univariate data with a bimodal independent variable. Regression of y on x is significantly positive over portions of data (black and blue lines) but lacks significance over the full range (red line).

The point estimates of optimal latency ϕ_m and ERR obtained previously are confirmed by Table 2. The next stage of analysis concerns confidence intervals for ERR at the optimal latency. Statistical inference in [2] was based on the Likelihood Ratio Test but it was wrongly assumed,

as Little [3] pointed out, that Wilks theorem held for the non-linear models so that LRT would be asymptotically χ^2 distributed, if the null hypothesis (specifying parameters in the model) were true.

One of the regularity conditions required for Wilks Theorem is that distinct values of the model parameters produce distinct probability distributions. In the two-phase model when $\sigma = 0$, $ERR = \beta D_\phi$ irrespective of the value of τ . The asymptotic properties of models with an indeterminate parameter (which cannot be identified from the distribution) have been analysed [18-21] but I was unable to use these methods and therefore took an intensive computational approach, which applies to the given set of records rather than asymptotically.

The parametric bootstrap is an established technique for finding confidence intervals in the absence of any information on the distribution of LRT. The percentile method refits the model to simulated data generated by samples from the model whose parameter values were obtained by fitting to the actual data. The BC_a method adjusts for the fact that simulation may produce biased estimates of the statistic of interest (in this case ERR) and of its variance. Both methods gave good coverage with almost identical rates when tested on the stomach data,

and comparable confidence intervals for all the sites analysed. The BC_a method is much faster and generally preferable.

However, the underlying assumption of the parametric bootstrap is open to question. Perhaps the observed data arose from sampling at parameter values other than those obtained by fitting the model to that data. Confidence Intervals based on LRT avoid this assumption but depend on the critical value $t_{.95}$ used to reject the null hypothesis if $LRT > t_{.95}$.

If Wilks Theorem had applied, then LRT for testing $H_0: (\beta, \sigma, \tau) = (\beta_0, \sigma_0, \tau_0)$ vs. the alternative $(\beta, \sigma, \tau) \neq (\beta_0, \sigma_0, \tau_0)$ would have the asymptotic distribution $LRT \sim \chi^2$ on 3 d.f. if H_0 holds, for any H_0 . Thus $t_{.95} = F^{-1}(0.95) = 7.8147$ where F is the cumulative χ^2 on 3 d.f. would be the appropriate critical value, rejecting H_0 if $LRT > t_{.95}$.

In the absence of any theoretical prediction, the null distribution of LRT can still be estimated by Monte Carlo simulation but may depend on the choice of H_0 as seen in Additional File 1, Tables S1, S2, S3 and S4. In fact Additional File 1, Tables S2 and S3 show the null distribution of LRT_{2p-H_0} departs from χ^2 on 3 d.f. as $\sigma_0 \rightarrow 0$, while Additional File 1, Table S4 shows that the null distribution of LRT_{2p-lin} departs from χ^2 on 2 d.f. everywhere. Table 3 indicates that the simulated null distribution of LRT_{2p-H_0} is fairly independent of the parameters for the control covariates, and depends only on $H_0: (\beta, \sigma, \tau) = (\beta_0, \sigma_0, \tau_0)$. The null distributions when $\sigma_0 = 0$ are quite different from those when $\sigma_0 \gg 0$, as expected since it is $\sigma_0 = 0$ which causes the indeterminacy of the model and the failure of Wilks Theorem on this hyperplane. Gamma distributions give a reasonable fit to the simulated null distribution of LRT_{2p-H_0} in general (see Additional File 1, Tables S1, S2 and S3). When H_0 has $\sigma_0 = 0$, typical shape and rate parameters are $s \sim 2.24$ and $r \sim 0.63$, while for $\sigma_0 \gg 0$ $s \sim 1.5$ and $r \sim 0.5$ as predicted by Wilks Theorem. Figure 8, the probability plot for the stomach with $(\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$ shows the failure of Wilks Theorem and the close fit of simulated $LRT_{2p-H_0} = LRT_{2p-con}$ with a gamma distribution ($s = 2.418, r = 0.604$).

The Kolmogorov-Smirnov test against the fitted distribution is extremely sensitive and even when it distinguishes LRT from the fitted gamma, a probability plot may show close agreement. For example for the liver, with $(\beta_0, \sigma_0, \tau_0) = (7.297, 0, \text{arbitrary})$, the K-S test has $D = 0.058$ with simulated $p = 0.001$ but the plot (Figure 9) is fairly close.

Likewise, fitted gamma distributions generally give a reasonable fit to the null distribution of LRT_{2p-lin} with typical parameters $s \sim 1.79, r \sim 0.68$.




Figure 8
Simulated LRT at $H_0: (\beta, \sigma, \tau) = (0, 0, \tau_0)$ with fitted γ and χ^2 : stomach. At a given probability value, the red dot shows the corresponding quantile of the simulated values ($N = 1000$) of $LRT = LRT_{2p-H_0}$ for the stomach with the null hypothesis $H_0: (\beta_0, \sigma_0, \tau_0) = (0, 0, \text{arbitrary})$. For this H_0 , $LRT_{2p-H_0} = LRT_{2p-con}$. The black line shows quantiles of the fitted gamma distribution γ , with shape s and rate r . The blue line shows quantiles of the χ^2 (3 d.f.) distribution. The horizontal lines marked 8.960 and 7.815 show the 0.95 quantiles of γ and χ^2 (3 d.f.).

For the linear model, Additional File 1, Table S4 shows simulation of the null distribution of LRT_{lin-H_0} generally conforms to a χ^2 distribution on 1 d.f. as expected from Wilks theorem. However as $\beta_0 \rightarrow -0.5$, the null distribution approaches a γ distribution with




Figure 9
Simulated LRT at $H_0: (\beta, \sigma, \tau) = (7.297, 0, \tau_0)$ with fitted γ : liver. At a given probability value, the red dot shows the corresponding quantile of the simulated values ($N = 500$) of $LRT = LRT_{2p-H_0}$ for the liver with the null hypothesis $H_0: (\beta_0, \sigma_0, \tau_0) = (7.297, 0, \text{arbitrary})$. The black line shows quantiles of the fitted gamma distribution γ , with shape s and rate r . The horizontal line marked 7.375 shows the 0.95 quantile of γ .

shape = 0.5, rate = 1. Since $\beta_0 = -0.5$ specifies a boundary of the parameter space, the theory of mixture models [22] predicts, at the boundary, the null distribution of $LRT_{lin-H_0} \sim 1/2 \chi^2(1 \text{ d.f.}) = 1/2 \gamma(0.5, 0.5) = \gamma(0.5, 1)$. The confidence intervals shown in Figure 2 for liver and urinary cancers involve β values far from the boundary and Wilks theorem is valid in this region.

For all simulations and all cancer sites (Additional File 1, Tables S1, S2 and S3) the 95th percentile of the fitted gamma distributions and the 95th percentile of the simulated LRT_{2p-H_0} itself are all below 10. Additional File 1, Tables S1, S2, and S3 summarise nearly 50,000 simulations of LRT at a wide variety of randomly chosen values of H_0 . On that basis, $t_{.95} = 10$ is chosen as a conservative estimate applying throughout the parameter space for all cancer sites considered here. H_0 can be rejected whenever $LRT_{2p-H_0} > 10$, i.e. whenever $(\beta_0, \sigma_0, \tau_0)$ is outside the neighbourhood N_{10} of the fitted parameters $(\hat{\beta}, \hat{\sigma}, \hat{\tau})$. N_{10} is thus an appropriate neighbourhood, as defined in Methods.

Inside this neighbourhood Additional File 1, Table S1 shows gamma distributions generally fit the simulated LRT_{2p-H_0} very well, justifying the definition of $t'_{.95}$ from fitted gamma distributions within N_{10} . The intermediate choice $t'_{.95}$ is based on simulations inside and outside N_{10} and uses both the simulations and the fitted distributions to adjust the critical value upwards as either may be underestimates.

For the stomach, liver, and lung, confidence intervals for ERR obtained by the bootstrap (Table 2) or from simulation of LRT_{2p-H_0} (Table 4) are broadly similar, whichever critical value or bootstrap method is chosen. LRT intervals using $t'_{.95}$ show closer agreement with the bootstrap methods. For these 3 cancers, all the LRT-based intervals for ERR_1 and $ERR_{0.025}$ exclude 0 as do the bootstrap intervals, which are tighter. This validates the claim in [2] that ERR_1 is significantly elevated for the stomach, liver, and lung.

All five cancers show significant non-linearity of the dose response by LRT comparison of the two-phase and linear models (Table 5). For the stomach, liver, and leukaemia the two-phase model is preferable with $p \ll 0.001$, while for the lung and pancreas $p < 0.01$.

The previous discussion concerns behaviour at the optimal latency ϕ_m , an unknown parameter estimated from the data. BC_a intervals, comparable at ϕ_m to CIs obtained by other methods, were used to investigate ERR across a range of latencies, restricted to integers 5, 6, ... 44. Each cancer site has latency ranges in which BC_a CIs for ERR_1 and $ERR_{0.025}$ are strictly positive. Figure 5

illustrates this for the stomach and also shows that ERR is significantly raised when the dose is not modified by latency ($\phi = 6$ is below the minimum time-since-exposure in the 0 - 20 mSv cohort). With the linear model, liver and urinary cancers are significantly elevated over a range of long latencies, showing similar variation (Figures 1 and 2).

Fitting the two-phase model at ϕ_m , simulating new data and finding the simulated optimal latency $\hat{\phi}_m$ gives an estimate of the probability that the true value of ϕ_m lies in any given region. For the liver and stomach, this approach gives very strong evidence that ϕ_m lies in the regions where ERR_1 and $ERR_{0.025}$ are strictly positive, and where the two-phase model is clearly superior (by LRT) to the linear model. For the lung, the evidence on these points is still valid, though weaker. For leukaemia, there is strong evidence that ϕ_m lies in the region where the dose response is non-linear, and likewise in the region where the 95% CI for $ERR_{0.025}$ is strictly positive. However, with the variation in ϕ_m we cannot be confident that the 95% CI for ERR_1 is strictly positive.

Many results for the pancreas are considerably weaker than for other sites. Even at the optimal latency, the confidence intervals are extremely wide. With the BC_a method, the lower limit is attained as the minimum bootstrap value, and is assigned a probability > 0.025 . The "bias" and "acceleration" of the BC_a bootstrap sample are both large, unlike those for other sites. When the uncertainty in the optimal latency is determined by simulation at ϕ_m we cannot be confident that the true optimal latency for the pancreas lies within the range where $ERR > 0$ or where non-linearity is detected by LRT_{2p-lin} .

Up to this point, the primary aim was to test the validity of the conclusions in [2], and accordingly "city" was not included as a control covariate and the dose range remained at 0 - 20 mSv. A limited reanalysis including "city" in the baseline model and comparing the 0 - 20 mSv and 5 - 500 mSv dose ranges is shown in Tables 7 and 8. The higher dose range was chosen to include 10 mSv, but to exclude the lowest dose category in the LSS12 dataset. Above 5 mSv the revised dosimetry DS02 generally agrees with the DS86 dosimetry used here (and in [2]). Comparing these ranges tests whether the results from 0 - 20 mSv simply reflect some anomaly in the lowest dose category. With the exception of the pancreas, there is a striking similarity between results from the 0 - 20 mSv and 5 - 500 mSv dose ranges, which show comparable estimates of the optimal latency, latency ranges, and the Excess Relative Risk from 10 mSv.

I do not know if any other approach to baseline risk may explain these effects. However, significant non-linearity and positive ERR are also found for the stomach, liver and lung when the data is restricted to male or female subcohorts, with "city" included in the model (Table 9). Any possible interaction effects involving gender would disappear with the all-male or all-female data. As mentioned in [2] the use of log mean attained age was an adequate alternative to the full set of attained age categories, and alternative controls affected the estimates of ERR by no more than a factor of 2.

The results at 0.25 mSv ($ERR_{0.025}$) show that the risk detected here arises at extremely low doses. If there are doubts about the accuracy of the DS86 dosimetry, the question remains as to why the DS86 dose is a significant predictor of risk.

Overall, the results have several possible interpretations. They may reflect confounding by other covariates not shown in the public dataset, which may be correlated with the external dose used here (and in LSS12) and may also interact with radiation and may vary over time. Differences between the rural and urban populations may contribute to the non-linear effects. Or, these may be caused by gross underestimates of the external dose (unlikely) or by internal doses arising, for example, from "black rain". Such interpretations would be specific to the Japanese cohort, and would therefore cast doubt on using this data to predict radiation response elsewhere.

However, the results may also indicate that low doses of radiation do impact on cancer mortality, provided that latency is included in the model and the dose response is not constrained to be linear. In radiation cell biology, non-linear dose response is known for the bystander effect using a variety of endpoints and the two-phase model was proposed as a simplified form of a model for the bystander effect [16].

This paper does not reconsider any of these possible interpretations [2]. However, I hope it establishes the statistical validity of this analysis of the available public data for the 1950-1990 mortality cohort.

Conclusion

This reanalysis validates the main conclusions of [2]. Bootstrap methods and Monte Carlo simulation of LRT show that Excess Relative Risk for cancer mortality in Japanese A-bomb survivors exposed to external radiation doses below 20 mSv is positive, large, and significant for various cancers, as detected by models incorporating latency. The dose response is highly non-linear for the stomach, liver, lung, pancreas, and leukaemia. In each

case the two-phase model shows large Excess Relative Risk at 10 mSv external dose lagged by the optimal latency for the cancer. LRT-based 95% Confidence Intervals are strictly positive, except for leukaemia. Bootstrap BC_a 95% CIs are strictly positive for all five cancers over a range of latencies. Large, positive Excess Relative Risk is also found when the male and female data is analysed separately for the stomach, liver and lung.

When the optimal latency varies by simulation, the stomach, liver, lung and leukaemia still show non-linear dose response, and likewise $ERR > 0$ at 95% level for the stomach, liver, lung.

With "city" included as a control covariate in the two-phase model, similar estimates of latency and ERR at 10 mSv are obtained for the stomach, liver, lung, and leukaemia whether the dose range is 0 - 20 mSv or 5 - 500 mSv. Dose response for the liver, lung, and leukaemia is significantly non-linear in the 5 - 500 mSv range, particularly for the lung. Such results cannot be explained by any anomaly of the 0 - 5 mSv data.

The linear model finds significant results for the liver and urinary tract over a range of long latencies.

This analysis of cancer mortality in Japanese A-bomb survivors exposed to low doses of external radiation in 1945 shows significant non-linearity of dose response and significant large Excess Relative Risk over a range of latencies. These findings do not support the current ICRP recommended annual occupational dose limit of 20 mSv.

Abbreviations

BC_a : Bias-corrected accelerated; CEDR: Comprehensive Epidemiological Data Resource; CI: Confidence Interval; DS02: Dosimetry System 2002; DS86: Dosimetry System 1986; ERR: Excess Relative Risk; ICRP: International Commission on Radiological Protection; K-S: Kolmogorov-Smirnov; LF: Least Favourable; LRT: Likelihood Ratio Test; LSS: Life Span Study; MLE: Maximum Likelihood Estimate; mSv: milliSievert; p-y: person-years; RERF: Radiation Effects Research Foundation.

Competing interests

The author declares that they have no competing interests.

Authors' contributions

GD conceived of and designed the study and carried out the statistical analysis.

Additional material

Additional file 1

Contains index file for downloading 4 Tables, 3 Code Files, 2 Commentary Files, and 5 Data Files.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1476-069X-8-56-S1.ZIP>]

Acknowledgements

The very extensive simulations were shared out across a bank of PCs. Special thanks to Tom Bimpson, Phil Boyd, Jeremy Hawthorne, Peter Mayne, Paul Grunnill, Helen Marks, Paul Mayne, and Martin Grunnill for their help. Thanks to Chris Roberts for suggesting the use of R and the bootstrap, and to David Richardson for continuing correspondence and encouragement. Thanks to Duncan Thomas for pointing out the uncertainty in optimal latency, and for other criticisms during peer review. Thanks to Mark Little for criticisms of [2] which provoked this paper.

This work was not funded.

The data described in this report were obtained from the Radiation Effects Research Foundation (RERF) via the Comprehensive Epidemiologic Data Resource. RERF is a private foundation that is funded equally by the Japanese Ministry of Health and Welfare and the US Department of Energy through the US National Academy of Sciences. The conclusions reached in this report are mine and do not necessarily reflect the scientific judgement of RERF or its funding agencies.

References

- ICRP: 1990 Recommendations of the International Commission on Radiological Protection Publication 60, Annals of the ICRP 21 (1-3) Oxford; 1991.
- Dropkin G: **Low dose radiation and cancer in A-bomb survivors.** *Environ Health* 2007, **6**:1.
- Little Mark: **Statistical problems with analysis of Dropkin.** <http://www.ehjournal.net/content/6/1/1/comments#260548>.
- Pierce DA, Shimizu Y, Preston DL, Vaeth M and Mabuchi K: **Studies of the Mortality of Atomic bomb survivors. Report 12, Part I, Cancer: 1950-1990.** *Radiat Res* 1996, **146**(1):1-27.
- Dudley R: **MIT OpenCourseWare | Mathematics | 18.466 Mathematical Statistics, Spring 2003 | Lecture Notes.** <http://ocw.mit.edu/OcwWeb/Mathematics/18-466Mathematical-Statistics-Spring2003/LectureNotes/>.
- Efron B and Tibshirani RJ: *An Introduction to the Bootstrap.* New York: Chapman & Hall; 1993.
- Davison AC and Hinkley DV: *Bootstrap Methods and their Application.* Cambridge: Cambridge University Press; 1997.
- R Development Core Team: *R: A language and environment for statistical computing.* Vienna, Austria: R Foundation for Statistical Computing; 2007 <http://www.R-project.org>.
- RERF (Radiation Effects Research Foundation).** <http://www.rerf.or.jp/>.
- CEDR (Comprehensive Epidemiological Data Resource) Data File Set JALSSA03 File ID: R12CANC.** <http://cedr.lbl.gov/cgi-bin/spiface/find/cedrfile/?FILE=1040> accessed 19 September 2002.
- R source code based on Nash JC: *Compact Numerical Methods for Computers: Linear Algebra and Function Minimisation.* CRC Press; 1990.
- DiCiccio TJ and Efron B: **Bootstrap Confidence Intervals.** *Stat Sci* 1996, **11**(3):189-228. http://projecteuclid.org/DPubS/Repository/1.0/Disseminate?view=body&id=pdf_1&handle=euclid.ss/1032280214.
- Pinheiro JC and Bates DM: *Mixed-effects models in S and S-PLUS.* New York: Springer; 2000.
- Venables WN and Ripley BD: *Modern Applied Statistics with S* New York: Springer; 42002.
- Geyer C: **Kolmogorov-Smirnov and Lilliefors Tests.** *lecture notes Statistics 5601, Univ of Minnesota.* <http://www.stat.umn.edu/geyer/5601/examp/kolmogorov.html#one-test>.
- Brenner DJ, Little JB and Sachs RK: **The bystander effect in radiation oncogenesis: II. A quantitative model.** *Radiat Res* 2001, **155**(3):402-408.
- Geras'kin SA, Oudalova AA, Kim JK, Dikarev VG and Dikareva NS: **Cytogenetic effect of low dose γ -radiation in *Hordeum vulgare* seedlings: non-linear dose-effect relationship.** *Radiat Environ Biophys* 2007, **46**:31-41.
- Davies RB: **Hypothesis Testing When a Nuisance Parameter is Present Only Under the Alternative.** *Biometrika* 1977, **64**(2): 247-254.
- Davies RB: **Hypothesis Testing When a Nuisance Parameter is Present Only Under the Alternatives.** *Biometrika* 1987, **74**(1):33-43.
- Cheng RCH and Traylor R: **Non-Regular Maximum Likelihood Problems.** *J R Stat Soc Series B Stat Methodol* 1995, **57**(1):3-44. <http://www.jstor.org/pss/2346086>.
- Andrews DVM and Ploberger W: **Admissibility of the Likelihood Ratio Test When a Nuisance Parameter is Present Only Under the Alternative.** *Ann Stat* 1995, **23**(5):1609-1629.
- Self GS and Liang KY: **Asymptotic Properties of Maximum Likelihood Estimators and Likelihood Ratio Tests under Nonstandard Conditions.** *J Am Stat Assoc* 1987, **82**(398): 605-610.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

